Benchmark Reiterates Buy on Belite Bio, Maintains $57 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Buy rating on Belite Bio (NASDAQ:BLTE) and maintained a $57 price target.
May 16, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Buy rating on Belite Bio and maintained a $57 price target.
The reiteration of a Buy rating and the maintenance of a $57 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100